2.86  0.1 (3.62%)		04-29 14:05
Open: 2.81 High: 2.96 Volume: 89,145		Pre. Close: 2.76 Low: 2.71 Market Cap: 66(M)

Short term
Mid term
Targets	6-month :	3.93	1-year :	4.52
Resists	First :	3.37	Second :	3.87
Pivot price	2.99
Supports	First :	2.54	Second :	2.12
MAs	MA(5) :	2.93	MA(20) :	3.02
	MA(100) :	2.81	MA(250) :	0
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	21.4	D(3) :	27.3
RSI	RSI(14): 47.2
52-week	High :	13.19	Low :	1.62

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ TSBX ] has closed above bottom band by 39.5%. Bollinger Bands are 23.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	3.04 - 3.06	3.06 - 3.07
Low:	2.7 - 2.72	2.72 - 2.74
Close:	2.73 - 2.76	2.76 - 2.78

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.

Tue, 16 Apr 2024
Turnstone Biologics announces board member resignation By Investing.com - Investing.com

Tue, 16 Apr 2024
Turnstone Biologics appoints new board member - Investing.com ZA - Investing.com South Africa

Tue, 16 Apr 2024
Turnstone Biologics Announces Board Changes and New Chair - TipRanks.com - TipRanks

Fri, 12 Apr 2024
Short Interest in Turnstone Biologics Corp. (NASDAQ:TSBX) Grows By 42.9% - MarketBeat

Tue, 23 Jan 2024
Here's Why We're A Bit Worried About Turnstone Biologics' (NASDAQ:TSBX) Cash Burn Situation - Simply Wall St

Sun, 21 Jan 2024
Here's Why Turnstone Biologics (NASDAQ:TSBX) Must Use Its Cash Wisely - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	23 (M)
Shares Float	14 (M)
Held by Insiders	11.3 (%)
Held by Institutions	67.3 (%)
Shares Short	626 (K)
Shares Short P.Month	392 (K)

EPS	-4.79
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	4.26
Profit Margin	-286 %
Operating Margin	-305.3 %
Return on Assets (ttm)	-32.4 %
Return on Equity (ttm)	-65.3 %
Qtrly Rev. Growth	-100 %
Gross Profit (p.s.)	0
Sales Per Share	0.83
EBITDA (p.s.)	-2.43
Qtrly Earnings Growth	0 %
Operating Cash Flow	-66 (M)
Levered Free Cash Flow	-46 (M)

PE Ratio	-0.61
PEG Ratio	-0.1
Price to Book value	0.67
Price to Sales	3.43
Price to Cash Flow	-1.01

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.